研究单位：[1]Peking Union Medical College Hospital,Beijing,Beijing,China,100730[2]The Second Hospital of Hebei Medical University[3]Tianjin Medical University General Hospital[4]Cangzhou Central Hospital[5]Cangzhou People's Hospital[6]Affiliated Hospital of Hebei University[7]Nantong University[8]The First Affiliated Hospital of Anhui Medical University[9]Northern Jiangsu People's Hospital[10]First Affiliated Hospital of Wenzhou Medical University[11]Zhejiang University[12]Taishan Medical University Affiliated Hospital[13]Tianjin Third Central Hospital[14]Jinhua Central Hospital[15]Navy General Hospital, Beijing
研究目的：
The purpose of the present study is to assess the efficacy of methylprednisolone as an adjuvant therapy in patients with severe community-acquired pneumonia (CAP) (PSI 4-5). The hypothesis of the study is that methylprednisolone can decrease the mortality of severe CAP without any significant side effects,with reduction of the time to clinical stability and failure rate of treatment.
